scholarly journals Allogeneic Stem Cell Transplantation (Allo-Sct) in the Elderly Patients (Age > 65 Years) with Acute Myeloid Leukemia (AML) Is Safe and Effective

2012 ◽  
Vol 18 (2) ◽  
pp. S292
Author(s):  
D. Jagadeesh ◽  
J. Cerny ◽  
M. Ramanathan ◽  
G.D. Raffel ◽  
L. Petrillo-Deluca ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Elderly Patients ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Myeloid Leukemia ◽  
The Elderly ◽  
Acute Myeloid

scholarly journals Allogeneic Stem Cell Transplantation to cure Acute Myeloid Leukemia in elderly patients

1970 ◽  
Vol 1 (1) ◽  
pp. 43-49
Author(s):  
Pritesh Patel ◽  
Santosh Saraf ◽  
Damiano Rondelli
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Elderly Patients ◽  
Cell Transplantation ◽  
Patient Selection ◽  
Allogeneic Stem Cell Transplantation ◽  
Myeloid Leukemia ◽  
Cell Transplant ◽  
Acute Myeloid

Outcomes for elderly patients with acute myeloid leukemia (AML) remain poor with standard therapies. Historically this age group has been excluded from treatment with allogeneic stem cell transplantation (allo-SCT) due to worries of excessive treatment related morbidity and mortality. However, transplantation outcomes have dramatically improved in the last decade due to the widespread use of less ablative conditioning regimens, improved supportive care, and improved patient selection based on prognostic tools such as the hematopoietic cell transplant specific comorbidity index. These have all led to an increasing acceptance of allo-SCT as a potential treatment modality in elderly patients with AML. This review addresses current strategies for patient selection and efficacy data for allo-SCT in elderly patients with AML. DOI: http://dx.doi.org/10.3126/jaim.v1i1.5840 Journal of Advances in Internal Medicine. 2012; 1(1): 43-49

Sign in / Sign up

Export Citation Format

Share Document